Stay updated on Selonsertib for NASH F3 Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Selonsertib for NASH F3 Fibrosis Clinical Trial page.

Latest updates to the Selonsertib for NASH F3 Fibrosis Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.5.0 added. Several glossary/related items were removed, including Non-alcoholic fatty liver disease, MedlinePlus Genetics, and Revision: v3.4.3.SummaryDifference0.1%

- Check13 days agoChange DetectedAdded related topics: Nonalcoholic fatty liver disease and MedlinePlus Genetics to the study page.SummaryDifference0.0%

- Check20 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRemoved the related-topics metadata entries for 'Non-alcoholic fatty liver disease' and 'MedlinePlus Genetics'. These tags are auxiliary and do not alter the primary study information.SummaryDifference0.0%

- Check42 days agoChange DetectedAdded Non-alcoholic fatty liver disease and related topics (including MedlinePlus Genetics) and updated the site revision to v3.4.2; removed the government funding lapse notice (and the prior v3.4.1 revision). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check50 days agoChange DetectedA government funding notice banner was added and the page revision version updated. A non-critical glossary term related to nonalcoholic fatty liver disease was removed.SummaryDifference0.2%

Stay in the know with updates to Selonsertib for NASH F3 Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selonsertib for NASH F3 Fibrosis Clinical Trial page.